EUVIMED · CrossrefZeitschrift
Expert Opinion on Investigational Drugs
ISSN 1354-3784 · Informa UK Limited
Neueste Artikel
Are we moving forward from amisulpride? LB-102 ( N- methyl amisulpride) in acute schizophrenia
Targeted KIT inhibitors: paradigm shift in the treatment of systemic mastocytosis
Targeting MUC1 in colorectal cancer
Innovative therapies under clinical development for ALS treatment. Part 2: biologics and natural products
Emerging therapeutic strategies and clinical development of investigational agents for conventional chondrosarcoma
Safety, pharmacokinetics, pharmacodynamics and target-mediated drug disposition modeling of TST002, a sclerostin antibody, in men and postmenopausal women with low bone mineral density
Dual antigen targeting in extramedullary multiple myeloma
Evaluating early systemic therapies in the neoadjuvant setting for the treatment of urological cancers
Targeting the proteasome in Leishmania donovani : developments from preclinical to Phase I and II trials
Cannabinoid use in adults with sickle cell disease: therapeutic development and clinical insights
The impact of novel BET inhibitors on the treatment armamentarium of myelofibrosis
Darigabat and subtype-selective GABA-A modulation: pharmacology, clinical development, and translational challenges
Targeting the CD47/SIRPα interaction in cancer: opportunities in non-Hodgkin lymphoma
KAT6 inhibitors under investigation for solid tumors: the preclinical and early phase progress
Potential of IMNN-001 in epithelial ovarian cancer: assessment of clinical findings
Safety, tolerability, pharmacokinetics, immunogenicity, and pharmacodynamics of MG-ZG122, a long-acting humanized anti-thymic stromal lymphopoietin mAb, in healthy Chinese: a randomized, double-blind, placebo-controlled, dose-escalation, phase I study
Advancements of investigational agents for cancer cachexia: what clinical progress have we seen in the last 5 years?
IRAK signaling in cancers: mechanisms, targeting, and clinical implications
Androgen receptor pathway signaling inhibitors in development for prostate cancer therapy
Antibiotics and non-traditional antimicrobial agents for carbapenem-resistant Acinetobacter baumannii in Phase 1, 2, and 3 clinical trials
Mirdametinib, an FDA-Approved MEK1/2 inhibitor for adult and pediatric NF1-associated plexiform neurofibromas
Antibiotics and non-traditional antimicrobial agents for Pseudomonas aeruginosa in clinical phases 1, 2, and 3 trials
Prospects of current AXL-targeting therapies in early phase cancer trials
Acetylcholine and muscarinic receptor targeting in bipolar disorder: does xanomeline-trospium chloride and other investigational muscarinic agonists hold promise as mechanistically informed treatments for manic episodes, mixed features and cognitive deficits in bipolar disorder?
Phase 1 trials of BI 764198, a transient receptor potential channel 6 inhibitor, in healthy volunteers and participants with kidney impairment
Neuropathic pain management: a focused review of current treatments and novel data from main ongoing clinical trials
Pancreatic ductal adenocarcinoma (PDAC): clinical progress in the last five years
Tumor immunology and immunotherapy for endometrial cancer
Survodutide in MASH: bridging the gap between hepatic and systemic metabolic dysfunction
Dual blockade of endothelin A and angiotensin II type 1 receptors with sparsentan as a novel treatment strategy to alleviate IgA nephropathy
Jahrgänge
2026 · 572025 · 862024 · 1102023 · 1082022 · 1062021 · 1162020 · 1322019 · 1052018 · 952017 · 1402016 · 1282015 · 1452014 · 1552013 · 1522012 · 1652011 · 1452010 · 1492009 · 1682008 · 1792007 · 1712006 · 1412005 · 1372004 · 1872003 · 3042002 · 1332001 · 1632000 · 2081999 · 1551998 · 1501997 · 1471996 · 1321995 · 1271994 · 1211993 · 1691992 · 14
EUVIMED